CD79A and COVID-19: The in-house anti-SARS-CoV-2 IgG and IgA ELISAs tested in this study may be useful for diagnosing the infection caused by SARS-CoV-2 to control the spread of COVID-19 and may provide insight into the seroprevalence status of COVID-19.